Unity Biotechnology Inc. today announced 12- and 18-week data from its Phase 2 BEHOLD study of UBX1325, a senolytic Bcl-xL inhibitor, in patients with diabetic macular edema (DME). During a conference call held today, Unity officials detailed Phase 2 BEHOLD DME study (NCT04857996) 12- and 18-week data. “We have achieved a strong proof of concept …
This illustration represents the light-induced collapse of the nanoscale charge order in a 2D crystal of tantalum disulfide (star-shapes) and the generation of a hidden metastable metallic state (spheres). Credit: Frank Yi Gao Single-shot spectroscopy techniques provide scientists with a new understanding of a mysterious light-driven process. Harold “Doc” Edgerton, the late
SAN FRANCISCO and SUZHOU, China, July 31, 2022 /PRNewswire/ — Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, autoimmune, metabolic, ophthalmology and other major diseases, and Laekna Therapeutics, a clinical-stage biotechnology company dedicated to bringing ground-breaking therapies to cancer and liver …
